Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Axel Haupt's publication output changed over time?
ScholarIQpublication output · 2018–2025
Output declined50% over the shown period — from 2 works in 2018 to 1 in 2025.
2
1
2
2
3
1
1
2018201920202022202320242025
What are the most-cited papers on Axel Haupt?
ScholarIQmost cited works
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, Qiwei Wu, Yu Du, Sirel Gurbuz, Tamer Coskun, Axel Haupt, Zvonko Miličević, Mark L. Hartman
New England Journal of Medicine. 20231,028 Citations
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
Rohit Loomba, Mark L. Hartman, Eric Lawitz, Raj Vuppalanchi, Jérôme Boursier, Elisabetta Bugianesi, Masato Yoneda, Cynthia Behling, Oscar W. Cummings, Yuanyuan Tang, Bram Brouwers, Deborah A. Robins, Amir Nikooie, Mathijs C. Bunck, Axel Haupt, Arun J. Sanyal
New England Journal of Medicine. 2024850 Citations
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coşkun, Kyle W. Sloop, Corina Loghin, Jorge Alsina‐Fernandez, Shweta Urva, Krister Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, William C. Roell, Uma Kuchibhotla, Julie S. Moyers, Charles Benson, Ruth E. Gimeno, David A. D’Alessio, Axel Haupt
S2764545133. 2018847 CitationsOPEN ACCESS
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan P. Frías, Michael A. Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E. Gimeno, Zvonko Miličević, Deborah A. Robins, Axel Haupt
The Lancet. 2018810 Citations
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Sean Wharton, Thomas Blevins, Lisa Connery, Julio Rosenstock, Sohini Raha, Rong Liu, Xiaosu Ma, Kieren J. Mather, Axel Haupt, Deborah A. Robins, Edward Pratt, Christof Kazda, Маниге Кониг
New England Journal of Medicine. 2023431 Citations
Related on ScholarIQ
Accadis Hochschule Bad Homburg
Institution
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Paper
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
Paper
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Paper
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Paper
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Paper